In VivoBiopharma Financing Biopharma financings during the fourth quarter of 2022 totaled $17.5bn from 282 deals; of those, 53 financings met or exceeded the $100m mark. Overall, follow on public offerings (
ScripA dearth of innovative drug developers seeking public listings on China’s Nasdaq-like STAR Market has made investors scratch their heads, as the bourse, hailed as the country’s only stock market open
ScripTwo innovative drug-focused Chinese bioventures are trying their luck with public share sales on China’s Nasdaq-like STAR Market under the Shanghai Stock Exchange, ending a more than six-month break i